Compare DRVN & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRVN | CLDX |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2020 | 1995 |
| Metric | DRVN | CLDX |
|---|---|---|
| Price | $10.70 | $28.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $19.57 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 2.3M | 857.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.82 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,339,588,000.00 | $12,743,000.00 |
| Revenue This Year | N/A | $97.61 |
| Revenue Next Year | $2.10 | $252.01 |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | 1.54 | ★ 87.78 |
| 52 Week Low | $9.80 | $14.40 |
| 52 Week High | $19.74 | $31.85 |
| Indicator | DRVN | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 26.64 | 51.12 |
| Support Level | $9.92 | $24.70 |
| Resistance Level | $15.81 | $30.90 |
| Average True Range (ATR) | 0.46 | 1.22 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 40.95 | 1.88 |
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes. The company segments include: Maintenance, Car Wash, Paint, Collision & Glass, and Platform Services. It derives maximum revenue from Maintenance Segment. Geographically, the company operates into United States, Canada and Rest of the World.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.